Table 4. Currently Available Drugs for Multiple Myeloma by Pathway Category.

Drug Class	Name (Brand)
Proteasome inhibitor	Ixazomib (Ninlaro), Carfilzomib (Kyprolis), Bortezomib (Velcade), Marizomib
Immunomodulator	Pomalidmide (Pomalyst), Lenalidomide (Revlimid)
Alkylating agents	Mephalan (Alkeran), Cyclophosphamide (Cytoxan)
Corticosteroids	Dexamethasone (Decadron), Predinisone (Deltasone)
Histone deacetylase Inhibitor	Panobinostat (Farydak), Vorinostat (Zolinza), Romidepsin (Istodax)
Bisphosphonates	Zoledronic acid (Zometa), Pamidronate (Aredia)
Monoclonal antibodies	Daratumumab (Darzalex), Elotuzumab (Empliciti), Silituximab (Sylvant), Cetuximab (Erbitux)
Immunotoxin	Indatuximab ravtansine
Hedgehog pathway inhibitor	BMS 833923
mTOR	Everolimus (Afinitor)
Akt inhibitor	Perifosine, Afuresertib
Aggresome/autophagy	Hydroxychloroquine
Kinesin spindle protein inhibitor	Filanesib
Cyclin-dependent kinase 4/6 inhibitor	Palbociclib
MEK1/2 inhibitor	Selumtinib (Koselugo)

MEK = mitogen-activated protein kinase, mTOR = mammalian target of rapamycin